Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 18 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

2 trials in Phase 3/4

Results Transparency

0%

0 of 15 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
14(77.8%)
Phase 2
2(11.1%)
Phase 3
2(11.1%)
18Total
Phase 1(14)
Phase 2(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT06337981Phase 2Completed

Efficacy and Safety of AJU-S56 in Dry Eye Syndrome Patients

Role: collaborator

NCT06291194Phase 3Recruiting

Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients

Role: collaborator

NCT04679883Phase 2Unknown

Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease

Role: lead

NCT04104997Phase 1Completed

A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers

Role: lead

NCT03927170Phase 1Completed

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)

Role: lead

NCT03963362Phase 1Unknown

The Pharmacokinetics of GLA5PR Tablet According to the Renal Function

Role: lead

NCT03851341Phase 1Completed

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers

Role: lead

NCT02072213Phase 1Completed

A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers

Role: lead

NCT02952937Phase 1Completed

Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg

Role: lead

NCT02955472Phase 1Completed

Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg

Role: lead

NCT02303769Phase 3Completed

Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS

Role: lead

NCT02326987Phase 1Completed

A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS-NF1 Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects

Role: lead

NCT02327000Phase 1Completed

A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers

Role: lead

NCT01638273Phase 1Completed

PK Study of Pregabalin GLARS Tablet 150mg and IR Formulation After Multiple Dosing Under Fed Condition in Healthy Male Subjects

Role: lead

NCT01779492Phase 1Completed

A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers

Role: lead

NCT01829893Phase 1Completed

PK Comparison of GL2701 With Finasteride and Tamsulosin in Combination

Role: collaborator

NCT01568450Phase 1Completed

A Open-label, Single-dose Study to Investigate The Pharmacokinetics Between a GL2907 XL and Oxycontin CR Tab. 10mg in Healthy Male Volunteers

Role: lead

NCT01635751Phase 1Completed

A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects

Role: lead

All 18 trials loaded